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Objective: Severe mitral regurgitation is a frequent complication of end-
stage cardiomyopathy that contributes to heart failure and predicts a poor
survival. We studied the intermediate-term outcome of mitral reconstruc-
tion in 48 patients who had cardiomyopathy with severe mitral regurgita-
tion and were operated on between June 1993 and June 1997. Methods: Ages
ranged from 33 to 79 years (63 6 6 years) with left ventricular ejection
fractions of 8% to 25% (16% 6 3%). All patients were receiving maximal
drug therapy and were in New York Heart Association class III-IV with
severe, refractory 41 mitral regurgitation. Operatively, all 48 had under-
sized flexible annuloplasty rings inserted, 7 had coronary bypass grafts for
incidental disease, 11 had prior bypass grafts, and 11 also had tricuspid
valve repair. Results: One operative death occurred as a result of right
ventricular failure. Postoperative transesophageal echocardiography re-
vealed mild mitral regurgitation in 7 patients and no mitral regurgitation
in 41. There were 10 late deaths, 2 to 47 months after mitral reconstruction.
The 1- and 2-year actuarial survivals have been 82% and 71%. At a mean
follow-up of 22 months, the number of hospitalizations for heart failure has
decreased, and 1 patient has had heart transplantation. Significantly, New
York Heart Association class improved from 3.9 6 0.3 before the operation
to 2.0 6 0.6 after the operation. Twenty-four months after the operation,
left ventricular volume and sphericity have decreased, whereas ejection
fraction and cardiac output have increased. Conclusion: Whether this
favorable modification of left ventricular function and geometry will persist
remains unknown. However, mitral repair for cardiomyopathy with mitral
regurgitation allows new strategies for these patients. (J Thorac Cardiovasc
Surg 1998;115:381-8)
Heart transplantation is standard treatment forpatients with severe congestive heart failure
associated with end-stage heart disease. Although
successful, transplantation is hindered by donor
shortage and its limited applicability to older pa-
tients or those with comorbid diseases. As a result,
waiting times and recipient mortality on the waiting
list have increased. New surgical strategies to man-
age severe end-stage heart disease have therefore
evolved, including coronary artery revasculariza-
tion,1 cardiomyoplasty,2 left ventricular (LV) my-
oreduction surgery,3 and mitral valvular repair.4-7
Mitral regurgitation (MR) is a significant complica-
tion of end-stage cardiomyopathy, resulting from
dilation of the annular-ventricular apparatus,8 al-
tered ventricular geometry,9 or papillary muscle
dysfunction.10 MR exacerbates the volume overload
of the already dilated left ventricle, with progressive
annular dilation, worsened MR, and increased heart
failure, and it predicts a poor survival.11 Encouraged
by a prior study that assessed the feasibility of mitral
reconstruction in dilated cardiomyopathy, we under-
took this study to examine the intermediate out-
come of mitral reconstruction in terms of patient
survival and impact on heart failure and LV func-
tion, geometry, and remodeling.
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Methods
Between June 1993 and June 1997, 48 consecutive,
nonrandomized patients at the University of Michigan
Medical Center, with end-stage dilated cardiomyopathy
and refractory severe MR, were studied prospectively. All
patients had New York Heart Association (NYHA) class
III or IV congestive heart failure despite receiving maxi-
mized medical regimens and had severe LV systolic
dysfunction defined as an ejection fraction less than 25%
on angiography or radionuclide studies. Patients were
excluded from this study if there was evidence of primary
mitral valvular disease, if significant MR preceded cardio-
myopathy, if surgical intervention included revasculariza-
tion of viable myocardium, or if there was significant
aortic insufficiency.
MR was assessed by means of color-flow Doppler
ultrasonography; severity was graded as mild, moderate,
or severe. Quantitative analysis was performed by a single
experienced echocardiographer blinded to clinical data.
Measurements of LV, mitral annular, and outflow tract
diameters were made from two-dimensional images. LV
volumes, stroke volume, flows, regurgitant fractions, and
ejection fraction were calculated as previously described.4
Intraoperative and postoperative mitral gradients were
calculated by means of continuous wave Doppler ultra-
sonography.
Mitral valve reconstruction was performed through a
median sternotomy with standard cardiopulmonary by-
pass and hypothermic blood cardioplegic arrest in 37
patients and through a right thoracotomy with cold fibril-
latory arrest in 11 patients who had prior coronary bypass
grafting. Operations were performed with institutional
approval and informed consent.
All patients were contacted by telephone and personal
office visit for follow-up. A standardized questionnaire
was used for symptomatic evaluation, with physical activ-
ity being quantitated by self-report and compared with
preoperative functional status. The patients’ personal
physicians were also contacted in follow-up. Echocardio-
graphic follow-up studies were generally performed at the
University of Michigan. In the case of echocardiograms
performed elsewhere, original videotapes were sent for
quantitative analysis at the University of Michigan. All
data are presented as mean 6 standard deviation. Com-
parisons between preoperative and postoperative maxi-
mum volume of oxygen use, NYHA class, LV size,
volume, ejection fraction, regurgitant fraction, and for-
ward cardiac output were made by means of paired
Student’s t tests. Survival analysis was performed by the
Kaplan-Meier method. A significance level of 5% was
used when comparing differences.
Results
Forty-eight patients (31 men) were included in
the study. Their ages ranged from 33 to 79 years
(mean 63 6 6 years). Twenty patients were over the
age of 65 years. Twenty-four patients had nonisch-
emic dilated cardiomyopathy, and 24 had end-stage
ischemic cardiomyopathy, without ongoing isch-
emia, as defined by negative dobutamine echocar-
diographic functional testing and/or negative
positron emission tomography scanning for viability.
No patient was believed to have an acute myopathy.
Preoperatively, 40 patients had NYHA class IV
congestive heart failure and eight had class III. The
mean duration of documented cardiomyopathy or
symptomatic congestive heart failure was 46 years
(range 0 to 16 years). In the year before the opera-
tion, these patients had up to nine hospital admis-
sions for congestive heart failure. All patients were
receiving maximized medical therapy for congestive
heart failure including digoxin, diuretics, and after-
load reducers. Afterload reduction was accom-
plished with angiotensin-converting enzyme inhibi-
tors in all patients, with the addition of either
nitroglycerin or hydralazine, as indicated.
Preoperative ejection fraction ranged from 8% to
25% (mean 16% 6 3%). On coronary angiography,
seven patients with nonischemic dilated cardiomy-
opathy were found to have incidental coronary
artery disease. All patients with ischemic cardiomy-
opathy had significant coronary artery disease, with
prior coronary artery bypassing, but no ongoing
ischemia on functional testing. One patient with
ischemic cardiomyopathy had a history of recurrent
ventricular tachycardia. Another patient, with non-
ischemic cardiomyopathy, had hypereosinophilia
syndrome and was receiving interferon therapy. This
patient was not believed to be a candidate for
transplantation.
All patients underwent mitral reconstruction by
means of a remodeling ring annuloplasty, with im-
plantation of an undersized flexible remodeling ring.
No patient required a complex repair, inasmuch as
all patients were believed to have only annular
dilation or papillary muscle dysfunction (or both).
The average duration of cardiopulmonary bypass
was 124 6 24 minutes (range 66 to 198 minutes),
with an aortic crossclamp time of 71 6 11 minutes
(range 51 to 123 minutes). None of the patients
entered in this study had irreparable heart disease.
Coronary artery bypass grafts were placed in seven
patients with incidental coronary artery disease.
Additional procedures included De Vega tricuspid
annuloplasty in 11 patients, closure of an atrial
septal defect and a patent foramen ovale in 12, and
placement of implantable cardioverter-defibrillator
patches in one patient.
One operative death from right ventricular failure
occurred in a patient who died despite use of both
an intraaortic balloon pump and mechanical support
with a right ventricular assist device. All other
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patients survived the mitral reconstruction proce-
dure, despite their poor preoperative ventricular
function. All patients were weaned from cardiopul-
monary bypass with the use of a phosphodiesterase
inhibitor and norepinephrine. One patient required
support with an intraaortic balloon pump for 2 days.
Intraoperative transesophageal echocardiography
after annuloplasty and the discontinuation of car-
diopulmonary bypass revealed no MR in 41 patients
and trivial to mild MR in seven. The mean transmi-
tral gradient by intraoperative transesophageal
echocardiography was 31 mm Hg (range 2 to 6 mm
Hg). Postoperatively, seven patients required longer
than 24 hours of mechanical ventilator support after
mitral reconstruction, but only three patients re-
quired longer than 48 hours. There was one late
wound infection. No in-hospital deaths occurred,
other than the one previously described, and the
mean duration of hospitalization after the operation
was 9 6 4 days (range 5 to 37 days).
Follow-up was available for all patients. The
duration of follow-up in these patients has been 1 to
48 months, with 1- and 2-year survivals of 82% and
72%. At a mean follow-up of 22 months, all remain-
ing patients are in NYHA class I or II, with a mean
postoperative ejection fraction of 26% and a signif-
icant increase over the preoperative ejection frac-
tion in every patient and in the group as a whole. All
patients have continued to receive medical therapy
for congestive heart failure. Paradoxically, many
patients have had their afterload reduction medica-
tion increased, because they are now able to tolerate
higher doses of angiotensin-converting enzyme in-
hibitors. All patients have remained in their preop-
erative rhythm. All patients reported subjective im-
provement in their functional status after the
operation, citing activities routinely performed after
the operation for which exertional dyspnea was
previously prohibitive. The NYHA failure class sig-
nificantly fell for every patient individually and from
a mean of 3.9 6 0.2 to 1.8 6 0.4 for the entire group.
In patients in whom a preoperative comparison was
available, peak maximal volume of oxygen use dur-
ing exercise rose significantly from a mean of 14.5 to
18.6 ml oxygen per kilogram per minute.
Follow-up echocardiography at 1 week, 6 months,
and 24 months was available for all patients at those
time points. The mean transmitral gradient on fol-
low-up at 1 week was 3 6 1 mm Hg (range 1 to 5 mm
Hg). Matched preoperative and 24-month postoper-
ative measurements of LV size, Doppler-derived
flow, and volumes are summarized in Table I. All
patients had a marked reduction in sphericity, re-
gurgitant volume, and regurgitant fraction and sig-
nificantly improved LV ejection fraction, end-dia-
stolic volume, and end-systolic volume. Actuarial
survival is shown in Fig. 1.
There have been 10 late deaths in this group after
mitral valve reconstruction. Two late deaths were
related to complications developing after other op-
erative procedures—emergency appendectomy and
cholecystectomy. Other deaths have resulted from
continued heart failure, suicide, and sudden ventric-
ular arrhythmia.
Discussion
For patients with dilated cardiomyopathy, mortal-
ity is directly related to severity of ventricular sys-
tolic dysfunction.11 In addition, increased chamber
sphericity and, importantly, the presence of MR12
are markers of worsened prognosis. In a review of
this type of patients, 1-year mortality has been
reported between 54% and 70%.13 Furthermore, in
a study of 130 similar patients awaiting transplanta-
tion, 1-year survival was only 46% and independent
predictors of death were low forward stroke vol-
umes, ejection fraction less than 25%, and, again,
MR.14 The patients in this present study, therefore,
represented a high predicted mortality among pa-
tients with dilated cardiomyopathy, because they all
had severe LV systolic dysfunction, spherical
changes in LV geometry, and severe MR.
The pathogenesis of this myopathy-related MR is
multifactorial, and its understanding may lead to
better surgical approaches. In the absence of or-
ganic disease, MR is predominantly thought to
occur as a result of progressive dilation of the mitral
anulus with subsequent loss of coaptation of the
valve leaflets.15 In comparisons of patients with
dilated cardiomyopathy, with or without MR, those
Table I. Matched preoperative and 24-month
postoperative echocardiographic measurements to
compare preoperative and intermediate-term LV
end-diastolic volume (EDV), sphericity (diameter/
length, D/L), ejection fraction (EF), forward cardiac
output (CO), and regurgitant fraction (RF)
EDV
(ml) D/L
EF
(%)
CO
(L/min) RF (%)
Preop. 281 6 86 0.82 6 0.10 17 6 3 3.3 6 0.9 68 6 14
Postop. 206 6 88 0.74 6 0.07 26 6 8 5.2 6 1.1 15 6 14
Change 275 6 33 20.08 6 0.07 19 6 5 1.9 6 0.9 253 6 18
p Value ,0.001 0.005 0.008 0.001 ,0.001
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with MR have significantly greater mitral leaflet
orifice surface area and significantly larger dimen-
sions of the mitral valve anulus.8 As the size of the
mitral valve anulus increases, an increasing amount
of redundant mitral leaflet tissue, usually used for
coaptation of the leaflets, becomes available to
cover the surface area of the mitral valve orifice. A
large leaflet area is normally required for coapta-
tion, because mitral valve leaflet area is 21⁄2 times
greater than the area of the mitral valve orifice.16 As
more mitral leaflet tissue is used for coverage of the
enlarging mitral valve orifice, as the cardiomyopathy
progresses, a critical reduction in leaflet tissue avail-
able for coaptation is reached, so that coaptation of
the mitral leaflets becomes “ineffective” and a cen-
tral regurgitant jet of functional insufficiency begins
to develop.8, 17 Therefore, the most significant de-
terminant of mitral valve coaptation, leaflet orifice
area, and MR is the dimensions of the mitral valve
anulus. LV dimension is a less important factor in
“functional” MR, because chordal length and angu-
lation or papillary muscle length is not significantly
different in patients with idiopathic cardiomyopathy,
with or without MR.8
However, in ischemic cardiomyopathy, the mech-
anisms that contribute to MR are more complex and
may include “functional” MR through dilation of
the mitral valve anulus and “papillary muscle dys-
function.” Normal function of the mitral valve is
dependent on the structural and functional integrity
of the subvalvular apparatus.18 Papillary muscle
dysfunction is actually an unsuccessful coordination
of the entire mitral valve apparatus that includes the
anulus, leaflets, chordae tendineae, papillary mus-
cles, and the LV wall, rather than simply an isolated
disorder of the papillary muscle.19 In experimental
studies in dogs by Tsakiris and colleagues,20 isolated
injection of both papillary muscles that induced
fibrosis did not, by itself, induce MR. However, if
the free wall beneath the papillary muscles is made
fibrotic, so that regional asynergy develops, MR
develops as a result of restriction of motion of a
portion of the leaflets. Gorman and coworkers21
reported that ischemic MR appeared to be a multi-
factorial process that results in significant abnormal
deformational changes in the mitral valve anulus.
These ischemia-related changes all are thought to
result in an insufficient area of coaptation of the
mitral leaflet. All of these finding point to a rela-
tionship between mitral annular area, lack of coap-
tation, and the MR seen with myopathy. This rela-
tionship may explain why paradoxically an
undersized valvular repair can help a muscle prob-
lem. Although significant undersizing was used to
increase coaptation in all cases, no systolic anterior
motion of the anterior leaflet was noted. This sys-
Fig. 1. Actuarial survival after mitral valve reconstruction in cardiomyopathy, as determined by the
Kaplan-Meier method.
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tolic anterior motion was avoided by widening of the
aorto-mitral angle and increased LV size, seen in
myopathy.
The surgical management of MR has evolved
significantly. Early methods to correct MR simply
involved valve replacement with little understanding
of the adverse consequences that valve replacement
and interruption of anulus–papillary muscle conti-
nuity had on short- and long-term LV function.
Numerous clinical and experimental studies demon-
strate the importance of preserving anulus–papillary
muscle continuity of the mitral valve. Lillehei, Levy,
and Bonnabeau22 first reported on preservation of
papillary muscles and chordae tendineae and its
benefits on LV function after mitral valve replace-
ment. Along with Rushmer,23 who reported a high
incidence of postoperative “low cardiac output syn-
drome” after mitral valve replacement, these inves-
tigators subsequently introduced techniques of pres-
ervation of the mitral apparatus. Studies by
Hansen,24 Sarris,25 and their coworkers, using load-
independent measurements of LV contractility,
demonstrate that division of all chordae tendineae
was accompanied by a 47% reduction in maximal
LV elastance. Further, the effects of chordal detach-
ment and reattachment on LV function were as-
sessed by load-independent measurements of maxi-
mal elastance. When all chordae were detached, a
significant decline of LV contractility was seen,
which was subsequently restored to baseline levels
after the native chordae were reattached by repair of
the papillary muscles. As the contributions of the
mitral anulus and LV geometry to LV function are
further understood, surgeons better appreciate the
importance of maintaining chordal, annular, and
subvalvular continuity and mitral geometric rela-
tionships, which may be even more important in
patients with severely compromised LV function.
Because the availability of transplantation as ther-
apy for patients with cardiomyopathy is hindered,
there has been recent interest in the altered geom-
etry of LV dysfunction as it relates to cardiomyop-
athy. This pioneering work has been undertaken by
Batista’s group3 and others and has examined the
aberrations in LV mass/volume relationships in pa-
tients with cardiomyopathy. Furthermore, surgeons
have attempted to renormalize this relationship by
LV myoreduction surgery, also called partial LV
reduction surgery, reduction myoplasty, or the
Batista procedure. This procedure has met with
varying degrees of success. However, some survivors
appear to be doing well and have been put into
NYHA classes I and II. In Batista’s procedure a
rough mathematical formula is used to reduce the
LV mass/volume ratio to normal. This formula
entails a 3:1 ratio of LV circumference to LV
diameter, so that for a 10 cm diameter heart to be
reduced to a 3 cm diameter (or by 7 cm), the outside
circumference of the left ventricle must be reduced
by 21 cm (3 3 7). This procedure therefore throws
away a large amount of good LV mass, as opposed
to mitral reconstruction alone, in which no myocar-
dial mass is lost. With mitral valve reconstruction for
myopathy, a more normal LV mass/volume ratio is
reestablished, with larger LV volumes than have
been reported by Batista and others. The average
LV volume 24 months after operation in this study
was more than 200 ml, still quite abnormal, whereas
Batista and others have demonstrated an acute
reduction of LV volumes to roughly 90 to 100 ml at
the time of operation. However, inasmuch as there
is no loss of ventricular mass with mitral valve
reconstruction, an appropriate mass/volume ratio is
still obtained. Importantly, the surgical mortality
both at 30 days and at 1 year is much lower in our
present series than in any reported series of LV
reduction surgery.
Another possible mechanism by which mitral
valve reconstruction helps these myopathic hearts
may be acute remodeling of the base of the heart
from the undersizing of the mitral annular ring. This
has been shown by two-dimensional echocardiogra-
phy immediately in the operating room. This may
reestablish an ellipsoid shape to the base of the LV
cavity. Additionally, the incidence of sudden death
after mitral reconstruction in these patients has not
been excessive, perhaps because of the lack of a
large ventricular suture line, as in ventricular reduc-
tion surgery. Finally, with the Batista procedure, one
must differentiate the effect of abolishment of MR
alone versus the addition of myoreduction. A recent
study denotes that remodeling of LV geometry may
be rapid and complete in patients with resultant
regurgitant fractions of less than 30% after correc-
tion of MR alone.26 Our patients had a mean
residual regurgitation fraction of only 16% after the
operation, which could favor rapid LV remodeling.
As evidence, late echocardiographic analyses in our
patients revealed a decreased sphericity and LV
volume after the operation. These patients may be
undergoing slow auto-remodeling as opposed to
acute Batista remodeling from altering the angula-
tion of the base of the heart, stabilization of the
mitral anulus, or LV unloading that has induced a
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more favorable ventricular geometry. This phenom-
enon appears to occur more readily in the idiopathic
hearts than in the end-stage ischemic hearts, which
may have less potential for remodeling. Whatever
the mechanism, it is interesting to speculate on the
long-term effect of these types of LV remodeling
operations and whether the effect of unloading the
myocyte is permanent. Finally, however, it must be
noted that patients in our current series are a
carefully selected group who may have more severe
MR, slightly better function, smaller LV cavity size,
or a higher incidence of chronic illness, with fewer
patients receiving inotropic support.
In conclusion, mitral reconstruction by means of
annuloplasty effectively corrected MR in these pa-
tients with myopathy. Furthermore, despite high
risks, there was only one operative death and the
actuarial survivals were 82% and 72% at 1 and 2
years. Not only was survival improved, but func-
tional status has changed remarkably. Although
longer term follow-up with a greater number of
patients and perhaps case-matched controls is nec-
essary, we continue to be encouraged by these
intermediate results and believe that mitral recon-
struction offers a new strategy for patients with
end-stage cardiomyopathy.
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Discussion
Dr. Kent W. Jones (Salt Lake City, Utah). When the
group from the University of Michigan presented their
early outcome of mitral valve reconstruction in this group
of patients at the Western Thoracic Surgical Association
meeting in Squaw Valley in 1994, their results were
received with astonishment. Discussants of the paper
prefaced their remarks by such statements as:
“It would not have been intuitively obvious to me that
these patients would have benefited from this operation.”
“These are truly surprising results.” “I am flabbergasted.”
“These results are absolutely phenomenal.” Now, 3 years
later, we remain very impressed by these results.
The series now comprises 47 consecutive nonrandom-
ized patients with end-stage cardiomyopathy and severe
MR who were treated by mitral valve reconstruction using
a flexible annuloplasty ring. Some of the most impressive
and important facts resulting from this study are as
follows:
1. The mean time from documentation of the cardiomy-
opathy to operation was 4 years.
2. Only one operative death and no hospital deaths
occurred, and the mean hospital stay was only 9 days.
3. The 1-year actuarial survival was 82% and the 2-year
actuarial survival was 72%.
4. Postoperatively, all patients were in NYHA class I or II
and the mean left ventricular ejection fraction was
26%.
5. Nine patients were accepted for the operation, but
declined. Seven of these nine were dead within 8
months.
This procedure represents one of a spectrum of new
modalities that have evolved in the treatment of patients
with end-stage heart disease who would otherwise be
candidates for cardiac transplantation. However, given
the limitations imposed on transplantation because of
organ shortage, age, and its restricted applicability in
patients with concurrent disease, the results presented
here certainly provide another potential avenue of treat-
ment.
I have three questions: First, since this group of patients
has survived an average of 4 years after initial documen-
tation of their cardiomyopathy, do they represent a select
group? Most patients with end-stage heart disease have
died within this time frame.
Dr. Bolling. These are very carefully selected patients;
the vast majority of these patients were operated upon on an
outpatient basis. If we could do anything to get them out of
the hospital, off inotropic support, see them in the clinic, and
bring them back when they were in more stable condition,
we did that. As opposed to the Batista series and the
Cleveland Clinic series, I think we were operating on less
acutely ill patients. Only two patients in this series were
receiving inotropic support at the time we operated on them.
Dr. Jones. Second, inasmuch as MR is usually a late
complication of cardiomyopathy and is a poor prognostic
sign, what gave your group the impetus to undertake this
study?
Dr. Bolling. We saw patients who were on our trans-
plant list in whom MR developed late in the their course,
and then they would die before we could get a donor
organ for them. We asked ourselves, “What could we do
for these patients to tide them over to transplantation?”
Dr. Jones. Third, this study, like the initial early out-
come study, represents consecutive, nonrandomized pa-
tients. Would not a study using case-matched controls
offer more meaningful information in this group of pa-
tients?
Dr. Bolling. I think that is an absolutely great idea. A
multiinstitutional, case-matched, randomized study of this
operation versus mitral reconstruction plus myoreduction,
the so-called Batista procedure, would be indicated in this
group of patients. We do not have a control group, and we
should have a placebo or randomized approach to these
patients. We had planned to operate on these patients,
and then for various reasons (they became sick and died,
or they went away and we did not hear back from them)
we did not operate. They are not control patients; they are
not randomized; I do not want to put weight on those
patients. However, medical therapy for cardiomyopathy
yields pretty good results in this group of patients. Rou-
tine death rates on a heart transplant waiting list are no
longer 100% at 1 year with inhibition of angiotensin-
converting enzyme. However, mortality is very high in
those specific patients with 41 MR refractory to medical
therapy. These patients were similar to patients we would
have operated on. That is all we are implying.
Dr. David A. Fullerton (Winnetka, Ill.). Dr. Bolling,
since the last time you and I spoke about this, we have
operated on several patients who I think would fit into
your group. The preoperative ejection fraction has been
around 20% in all, and 2 weeks after the operation the
ejection fraction was about 26% or 27% according to
multiple gated acquisition scan.
According to what has been written about doing coro-
nary bypass surgery in patients who have very poor
ejection fractions, those patients who had coronary bypass
had a better long-term survival if they had an electrophysi-
ologic study after the operation. I extrapolated from those
data and asked our electrophysiology group to do studies
in patients getting mitral repairs. What we found was that
most of this group had a positive electrophysiologic study
and received an automatic implantable cardioverter-defi-
brillator. Have you given any thought to that, and might
that strategy offer an enhanced long-term survival for this
group of patients?
Dr. Bolling. That is a good question, Dr. Fullerton. We
have looked at the same issue in these patients—whether
over the long term we should add an automatic implant-
able cardioverter-defibrillator or whether all these pa-
tients should be receiving amiodarone. There is an inci-
dence of late sudden death, both in the idiopathic group
and in the ischemic group, as is true in all patients with
cardiomyopathy, and that is certainly an interesting sug-
gestion.
Dr. Sulaiman B. Hasan (Karachi, Pakistan). I have two
questions: What was the incidence of significant pulmo-
nary hypertension and tricuspid regurgitation, and did you
select on the basis of that?
Dr. Bolling. We had wide ranges of pulmonary hyper-
tension from some patients having supersystemic pulmo-
nary artery pressures at the time of operation. The
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incidence of significant tricuspid regurgitation is about
25% in this series, and about 25% of those patients
underwent tricuspid annuloplasties. That was usually an
intraoperative decision.
Dr. Hasan. Did you see any difference in the morbidity
in the patients who had higher pulmonary artery pres-
sures?
Dr. Bolling. No.
Dr. Hasan. What kind of annuloplasty ring do you use?
Dr. Bolling. We used both a flexible and a semiflexible
ring. One is a Physio ring (Baxter Healthcare Corp.,
Irvine, Calif.) and the other is the Duran ring (Medtronic,
Inc., Minneapolis, Minn.). We are actually trying to
randomize between a totally flexible ring and a semiflex-
ible ring in terms of patient outcome, but we do not have
enough patients to say anything about that yet.
Dr. Jay I. LaBourene (Belvedere, Calif.). I was involved
in the early part of this study as a resident. At that time we
were measuring the intertrigonal distance to determine
ring size. I have operated on about a dozen patients
similar to these using the intertrigonal technique with very
good results. I am curious about the fact that you are now
downsizing the anulus much more than we used to. What
stimulated you to do that? Are you finding geometric or
clinical advantages in doing so?
Dr. Bolling. As you know, we would downsize one size
or so to try to eliminate MR. However, as we followed up
these patients with echocardiography, we noted that we
were abolishing the MR, the 2-year data were excellent,
and the base of the heart was being reduced. The smaller
we made the anulus, the more the base of the heart came
in and the more ellipsoid the long radius of the heart
became from base to apex. We thought not only were we
going to abolish MR, but we were going to acutely
remodel the heart to an ellipse. The long-axis radius was
going to have more curvature and the radius was going to
change. We started downsizing more and more. Now we
are basically putting in the smallest rings that we can, and
we have not seen mitral stenosis clinically in any patient.
Dr. Robert M. Kass (Los Angeles, Calif.). I am curious
about the causes of death in the patients who died in the
follow-up period. Also, it appears that there is going to be
a significant fall-off as you monitor the patients. Are these
patients still maintained on your transplant list?
Dr. Bolling. The causes of death are listed in the article.
The biggest cause of death was continued heart failure.
We are looking at molecular markers. We would like to
see norepinephrine levels and other indicators that would
tell us that this patient will never get better. Two of our
patients have later required elective general surgery op-
erations, a cholecystectomy and then an emergency ap-
pendectomy, and they both died. One woman committed
suicide. I think there probably will not be a sustained
change in the myocytes. Whether these myocytes are
permanently damaged and whether left ventricular func-
tion can recover permanently are matters of controversy.
The numbers we have at 3 and 4 years are not big enough
to allow us to say anything about long-term results,
although the Kaplan-Meier curve does fall off at 36 and 48
months.
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